

## Multiple Myeloma

Resource	Address
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet</i> . 2020;396(10254):839-852.	<a href="https://pubmed.ncbi.nlm.nih.gov/32888407/">https://pubmed.ncbi.nlm.nih.gov/32888407/</a>
Anderson JLD, Munshi NC, Shah N, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. <i>J Clin Oncol</i> . 2021;39(15_suppl):8016-8016.	<a href="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8016">https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8016</a>
Axicabtagene ciloleucel (Yescarta®) PI 2022	<a href="https://www.fda.gov/files/vaccines%2C%20blood%20&amp;%20biologics/published/Package-Insert-YESCARTA.pdf">https://www.fda.gov/files/vaccines%2C%20blood%20&amp;%20biologics/published/Package-Insert-YESCARTA.pdf</a>
Belantamab mafodotin-blmf (Blenrep) PI 2020	<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf</a>
Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet</i> . 2021;398(10297):314-324.	<a href="https://pubmed.ncbi.nlm.nih.gov/34175021/">https://pubmed.ncbi.nlm.nih.gov/34175021/</a>
Borrello I. Can we change the disease biology of multiple myeloma? <i>Leuk Res</i> . 2012;36 Suppl 1(0 1):S3-S12.	<a href="https://pubmed.ncbi.nlm.nih.gov/23176722/">https://pubmed.ncbi.nlm.nih.gov/23176722/</a>
Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. <i>Nat Med</i> . 2003;9(3):279-286.	<a href="https://pubmed.ncbi.nlm.nih.gov/12579196/">https://pubmed.ncbi.nlm.nih.gov/12579196/</a>

Resource	Address
<p><b>Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. <i>Nat Rev Clin Oncol.</i> 2018;15(1):31-46.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/28857075/">https://pubmed.ncbi.nlm.nih.gov/28857075/</a></p>
<p><b>Bruno B, Wäsch R, Engelhardt M, et al. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica.</i> 2021;106(8):2054-2065.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/33792221/">https://pubmed.ncbi.nlm.nih.gov/33792221/</a></p>
<p><b>Chang ZL, Chen YY. CARs: Synthetic immunoreceptors for cancer therapy and beyond. <i>Trends Mol Med.</i> 2017;23(5):430-450.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/28416139/">https://pubmed.ncbi.nlm.nih.gov/28416139/</a></p>
<p><b>Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. <i>N Engl J Med.</i> 2019;381(8):727-738.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/31433920/">https://pubmed.ncbi.nlm.nih.gov/31433920/</a></p>
<p><b>Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. <i>Front Immunol.</i> 2018;9:1821.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/30147690/">https://pubmed.ncbi.nlm.nih.gov/30147690/</a></p>
<p><b>Ciltacabtagene autoleucel (Carvykt™) PI 2022</b></p>	<p><a href="https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf">https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf</a></p>
<p><b>Costello C, Derman BA, Kocoglu MH, et al. Clinical trials of BCMA-targeted CAR-T cells utilizing a novel non-viral transposon system. <i>Blood.</i> 2021;138(Supplement 1):3858-3858. doi:10.1182/blood-2021-151672</b></p>	<p><a href="https://ashpublications.org/blood/article/138/Supplement%201/3858/481060/Clinical-Trials-of-BCMA-Targeted-CAR-T-Cells">https://ashpublications.org/blood/article/138/Supplement%201/3858/481060/Clinical-Trials-of-BCMA-Targeted-CAR-T-Cells</a></p>
<p><b>D'Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? <i>Leukemia.</i> 2020;34(1):21-34.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/31780814/">https://pubmed.ncbi.nlm.nih.gov/31780814/</a></p>
<p><b>Durie BGM. Multiple myeloma: concise review of the disease and treatment options. 2018.</b></p>	<p><a href="https://imf-d8-prod.s3.us-west-1.wasabisys.com/resource/ConciseReview.pdf">https://imf-d8-prod.s3.us-west-1.wasabisys.com/resource/ConciseReview.pdf</a></p>

Resource	Address
<p><b>Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 Study. <i>Ophthalmol Ther.</i> 2020;9(4):889-911.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/32712806/">https://pubmed.ncbi.nlm.nih.gov/32712806/</a></p>
<p><b>Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia.</i> 2019;33(9):2266-2275.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/30858549/">https://pubmed.ncbi.nlm.nih.gov/30858549/</a></p>
<p><b>Gasparetto C, Lentzsch S, Schiller G, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>E J Haem.</i> 2020;2(1):56-65.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/35846104/">https://pubmed.ncbi.nlm.nih.gov/35846104/</a></p>
<p><b>Gasparetto C, Schiller GJ, Tuchman SA, et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. <i>Br J Cancer.</i> 2022;126(5):718-725.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/34802051/">https://pubmed.ncbi.nlm.nih.gov/34802051/</a></p>
<p><b>Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet.</i> 2020;396(10262):1563-1573.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/33189178/">https://pubmed.ncbi.nlm.nih.gov/33189178/</a></p>
<p><b>Guglielmelli T, Palumbo A. Multiple myeloma: is a shift toward continuous therapy needed to move forward?. <i>Expert Rev Hematol.</i> 2015;8(3):253-256.</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/25582032/">https://pubmed.ncbi.nlm.nih.gov/25582032/</a></p>

Resource	Address
<p>Harrison SJ, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM). 2020 ASH Annual Meeting &amp; Exposition. Abstract 181.</p>	<p><a href="https://ashpublications.org/blood/article/138/Supplement%201/900/482650/A-Phase-1-First-in-Human-Study-of-Tnb-383B-a-BCMA">https://ashpublications.org/blood/article/138/Supplement%201/900/482650/A-Phase-1-First-in-Human-Study-of-Tnb-383B-a-BCMA</a></p>
<p>Idecabtagene vicleucel (Abecma®) PI 2021</p>	<p><a href="https://packageinserts.bms.com/pi/pi_abecma.pdf">https://packageinserts.bms.com/pi/pi_abecma.pdf</a></p>
<p>Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncol.</i> 2016;17(8):e328-e346.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/27511158/">https://pubmed.ncbi.nlm.nih.gov/27511158/</a></p>
<p>Kumar SK, et al. Results from Lummicar-2: A phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and/or refractory multiple myeloma. 2020 ASH Annual Meeting and Exposition.</p>	<p><a href="https://ash.confex.com/ash/2020/webprogram/Paper139802.html">https://ash.confex.com/ash/2020/webprogram/Paper139802.html</a></p>
<p>Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. <i>Mayo Clin Proc.</i> 2004;79(7):867-874.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/15244382/">https://pubmed.ncbi.nlm.nih.gov/15244382/</a></p>
<p>Kumar SK. Updates in the treatment of multiple myeloma. <i>J NCCN.</i> 2021;19(5.5):648-651.</p>	<p><a href="https://jnccn.org/view/journals/jnccn/19/5.5/article-p648.xml">https://jnccn.org/view/journals/jnccn/19/5.5/article-p648.xml</a></p>
<p>Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia.</i> 2016;30(5):1005-1017.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/26710887/">https://pubmed.ncbi.nlm.nih.gov/26710887/</a></p>

Resource	Address
<p>Lee DW, Santomaso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol Blood Marrow Transplant</i>. 2019;25(4):625-638.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/30592986/">https://pubmed.ncbi.nlm.nih.gov/30592986/</a></p>
<p>Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. <i>Protein Cell</i>. 2017;8(8):573-589.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/28434147/">https://pubmed.ncbi.nlm.nih.gov/28434147/</a></p>
<p>Lim WA, June CH. The principles of engineering immune cells to treat cancer. <i>Cell</i>. 2017;168(4):724-740.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/28187291/">https://pubmed.ncbi.nlm.nih.gov/28187291/</a></p>
<p>Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncol</i>. 2019;20(1):31-42.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/30518502/">https://pubmed.ncbi.nlm.nih.gov/30518502/</a></p>
<p>Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncol</i>. 2020;21(2):207-221.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/31859245/">https://pubmed.ncbi.nlm.nih.gov/31859245/</a></p>
<p>Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. <i>Cancer</i>. 2021;127(22):4198-4212.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/34314018/">https://pubmed.ncbi.nlm.nih.gov/34314018/</a></p>
<p>Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. <i>Clin Cancer Res</i>. 2011;17(6):1264-1277.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/21411442/">https://pubmed.ncbi.nlm.nih.gov/21411442/</a></p>
<p>Majors B, et al. Initial Experience In US commercial manufacturing of tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell therapy for pediatric rRelapsed/refractory B-cell precursor acute</p>	<p><a href="https://library.ehaweb.org/eha/2018/stockholm/215467/brian.majors.initial.experience.in.us.commercial.manufacturing.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dps1156">https://library.ehaweb.org/eha/2018/stockholm/215467/brian.majors.initial.experience.in.us.commercial.manufacturing.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dps1156</a></p>

Resource	Address
<p>lymphoblastic leukemia. European Hematology Association annual meeting. 2018. Abstract PS1156.</p>	
<p>Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. <i>Nat Rev Clin Oncol</i>. 2017;14(2):100-113.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/27531699/">https://pubmed.ncbi.nlm.nih.gov/27531699/</a></p>
<p>Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. <i>J Clin Oncol</i>. 2022;JCO2200842.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/35658469/">https://pubmed.ncbi.nlm.nih.gov/35658469/</a></p>
<p>Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. <i>Blood</i>. 2021;138:549.</p>	<p><a href="https://www.sciencedirect.com/science/article/pii/S0006497121025416">https://www.sciencedirect.com/science/article/pii/S0006497121025416</a></p>
<p>Martin, T, et al. Updated Results From CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Abstract 549. 2021 ASH Annual Meeting &amp; Exposition</p>	<p><a href="https://www.sciencedirect.com/science/article/pii/S0006497121025416">https://www.sciencedirect.com/science/article/pii/S0006497121025416</a></p>
<p>Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i>. 2011;118(3):529-534.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/21482708/">https://pubmed.ncbi.nlm.nih.gov/21482708/</a></p>
<p>Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. <i>Oncologist</i>. 2016;21(5):608-617.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/27009942/">https://pubmed.ncbi.nlm.nih.gov/27009942/</a></p>

Resource	Address
Moreau P, et al: Updated results from MajesTEC-1. 2021 ASH Annual Meeting & Exposition. Abstract 896.	<a href="https://ashpublications.org/blood/article/138/Supplement%201/896/482626/Updated-Results-from-MajesTEC-1-Phase-1-2-Study-of">https://ashpublications.org/blood/article/138/Supplement%201/896/482626/Updated-Results-from-MajesTEC-1-Phase-1-2-Study-of</a>
Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. <i>N Engl J Med</i> . 2022;387(6):495-505.	<a href="https://pubmed.ncbi.nlm.nih.gov/35661166/">https://pubmed.ncbi.nlm.nih.gov/35661166/</a>
Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncol</i> . 2021;22(3):e105-e118.	<a href="https://pubmed.ncbi.nlm.nih.gov/33662288/">https://pubmed.ncbi.nlm.nih.gov/33662288/</a>
Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. <i>Nat Rev Cancer</i> . 2012;12(5):335-348.	<a href="https://pubmed.ncbi.nlm.nih.gov/22495321/">https://pubmed.ncbi.nlm.nih.gov/22495321/</a>
Morgan RA, Boyerinas B. Genetic modification of T cells. <i>Biomedicines</i> . 2016;4(2):9.	<a href="https://pubmed.ncbi.nlm.nih.gov/28536376/">https://pubmed.ncbi.nlm.nih.gov/28536376/</a>
Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. <i>Nat Rev Immunol</i> . 2022;22(2):85-96.	<a href="https://pubmed.ncbi.nlm.nih.gov/34002066/">https://pubmed.ncbi.nlm.nih.gov/34002066/</a>
Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple Myeloma. <i>N Engl J Med</i> . 2021;384(8):705-716.	<a href="https://pubmed.ncbi.nlm.nih.gov/33626253/">https://pubmed.ncbi.nlm.nih.gov/33626253/</a>
National Cancer Institute. Cancer Stat Facts: Multiple Myeloma.	<a href="https://seer.cancer.gov/statfacts/html/mulmy.html">https://seer.cancer.gov/statfacts/html/mulmy.html</a>
National Comprehensive Cancer Network (NCCN). Multiple Myeloma Guidelines v5.2022.	<a href="https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf">https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf</a>
NCT03601078, NCT03651128, NCT04196491, NCT04133636, NCT04181827, NCT04923893	<a href="https://Clinicaltrials.gov">https://Clinicaltrials.gov</a>

Resource	Address
<p>Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. <i>Nat Rev Clin Oncol</i>. 2018;15(1):47-62.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/28925994/">https://pubmed.ncbi.nlm.nih.gov/28925994/</a></p>
<p>Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i>. 2015;125(20):3085-3099.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/25838342/">https://pubmed.ncbi.nlm.nih.gov/25838342/</a></p>
<p>Nooka AK, Moreau P, Usmani SZ, et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. <i>J Clin Oncol</i>. 2022;40(16_suppl):8007-8007.</p>	<p><a href="https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8007">https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8007</a></p>
<p>Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. <i>J Clin Oncol</i>. 2015;33(26):2863-2869.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/26240224/">https://pubmed.ncbi.nlm.nih.gov/26240224/</a></p>
<p>Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. <i>J Hematol Oncol</i>. 2014;7:78.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/25316614/">https://pubmed.ncbi.nlm.nih.gov/25316614/</a></p>
<p>Park JH, et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. 2015 ASH Annual Meeting &amp; Exposition.</p>	<p><a href="https://ash.confex.com/ash/2015/webprogram/scheduler/Paper86688.html">https://ash.confex.com/ash/2015/webprogram/scheduler/Paper86688.html</a></p>



Resource	Address
<p>Raje NS, Berdeja JG, Lin Y, et al. <b>bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: updated results from a multicenter phase I study.</b> <i>J Clin Oncol.</i> 2018;36(15_suppl):8007-8007.</p>	<p><a href="https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8007">https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8007</a></p>
<p>Raje NS, Shah N, Jagannath S, et al. <b>Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma.</b> <i>Blood.</i> 2021;138(Supplement 1):548-548.</p>	<p><a href="https://ashpublications.org/blood/article/138/Supplement%201/548/479384/Updated-Clinical-and-Correlative-Results-from-the">https://ashpublications.org/blood/article/138/Supplement%201/548/479384/Updated-Clinical-and-Correlative-Results-from-the</a></p>
<p>Rajkumar SV, Harousseau JL, Durie B, et al. <b>Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.</b> <i>Blood.</i> 2011;117(18):4691-4695.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/21292775/">https://pubmed.ncbi.nlm.nih.gov/21292775/</a></p>
<p>Rajkumar SV. <b>Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.</b> <i>Am J Hematol.</i> 2020;95(5):548-567.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/32212178/">https://pubmed.ncbi.nlm.nih.gov/32212178/</a></p>
<p>Richard S, Richter J, Jagannath S. <b>Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.</b> <i>Future Oncol.</i> 2020;16(19):1331-1350.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/32511022/">https://pubmed.ncbi.nlm.nih.gov/32511022/</a></p>
<p>Richardson PG, Barlogie B, Berenson J, et al. <b>A phase 2 study of bortezomib in relapsed, refractory myeloma.</b> <i>N Engl J Med.</i> 2003;348(26):2609-2617.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/12826635/">https://pubmed.ncbi.nlm.nih.gov/12826635/</a></p>
<p>Richardson PG, Barlogie B, Berenson J, et al. <b>Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.</b> <i>Cancer.</i> 2006;106(6):1316-1319.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/16470606/">https://pubmed.ncbi.nlm.nih.gov/16470606/</a></p>
<p>Richardson PG, San Miguel JF, Moreau P, et al. <b>Interpreting clinical trial data in multiple</b></p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/30413684/">https://pubmed.ncbi.nlm.nih.gov/30413684/</a></p>

Resource	Address
<p>myeloma: translating findings to the real-world setting. <i>Blood Cancer J.</i> 2018;8(11):109.</p>	
<p>Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. <i>Nat Rev Cancer.</i> 2003;3(1):35-45.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/12509765/">https://pubmed.ncbi.nlm.nih.gov/12509765/</a></p>
<p>Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. <i>Br J Haematol.</i> 2012;158(6):727-738.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/22804669/">https://pubmed.ncbi.nlm.nih.gov/22804669/</a></p>
<p>Sanchez L, Barley K, Richter J, et al. Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Rev Hematol.</i> 2020;13(9):943-958.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/32731770/">https://pubmed.ncbi.nlm.nih.gov/32731770/</a></p>
<p>Sanchez L, Richter J, Cho HJ, et al. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. <i>Ther Adv Hematol.</i> 2021;12:2040620720987075.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/33613930/">https://pubmed.ncbi.nlm.nih.gov/33613930/</a></p>
<p>Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline [published correction appears in <i>J Clin Oncol.</i> 2022 Mar 10;40(8):919]. <i>J Clin Oncol.</i> 2021;39(35):3978-3992.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/34724386/">https://pubmed.ncbi.nlm.nih.gov/34724386/</a></p>
<p>Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell Lymphoma. <i>N Engl J Med.</i> 2019;380(1):45-56.</p>	<p><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1804980">https://www.nejm.org/doi/full/10.1056/nejmoa1804980</a></p>
<p>Sebag M, et al: Elranatamab (PF-06863135), a B-cell maturation antigen targeted CD3-</p>	<p><a href="https://ashpublications.org/blood/article/138/Supplement%201/895/482627/Elranatamab-">https://ashpublications.org/blood/article/138/Supplement%201/895/482627/Elranatamab-</a></p>

Resource	Address
engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma. 2021 ASH Annual Meeting & Exposition. Abstract 895.	<a href="https://www.fda.gov/oc/label/2019/212306s000lbl.pdf">PF-06863135-a-B-Cell-Maturation?searchresult=1</a>
Selinexor (Xpovio™) PI 2019	<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf</a>
Shalabi H, Gust J, Taraseviciute A, et al. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. <i>Nat Rev Clin Oncol</i> . 2021;18(6):363-378.	<a href="https://pubmed.ncbi.nlm.nih.gov/33495553/">https://pubmed.ncbi.nlm.nih.gov/33495553/</a>
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. <i>CA Cancer J Clin</i> . 2022;72(1):7-33.	<a href="https://pubmed.ncbi.nlm.nih.gov/35020204/">https://pubmed.ncbi.nlm.nih.gov/35020204/</a>
Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma <i>Haematologica</i> . 2016;101(4):396-406.	<a href="https://pubmed.ncbi.nlm.nih.gov/27033237/">https://pubmed.ncbi.nlm.nih.gov/27033237/</a>
Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. <i>Haematologica</i> . 2016;101(4):396-406.	<a href="https://pubmed.ncbi.nlm.nih.gov/27033237/">https://pubmed.ncbi.nlm.nih.gov/27033237/</a>
Sonneveld P, De Wit E, Moreau P. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. <i>Crit Rev Oncol Hematol</i> . 2017;112:153-170.	<a href="https://pubmed.ncbi.nlm.nih.gov/28325256/">https://pubmed.ncbi.nlm.nih.gov/28325256/</a>
Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. <i>J Hematol Oncol</i> . 2021;14(1):115. Published 2021 Jul 23.	<a href="https://pubmed.ncbi.nlm.nih.gov/34301270/">https://pubmed.ncbi.nlm.nih.gov/34301270/</a>
Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and	<a href="https://pubmed.ncbi.nlm.nih.gov/23588715/">https://pubmed.ncbi.nlm.nih.gov/23588715/</a>

Resource	Address
therapeutic implications. <i>Leukemia</i> . 2014;28(1):155-165.	
Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> . 2014;123(20):3128-3138.	<a href="https://pubmed.ncbi.nlm.nih.gov/24569262/">https://pubmed.ncbi.nlm.nih.gov/24569262/</a>
Tisagenlecleucel (Kymriah®) PI 2022	<a href="https://www.fda.gov/media/107296/download">https://www.fda.gov/media/107296/download</a>
Usmani SZ, Martin TG, Berdeja JG, et al. Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. <i>J Clin Oncol</i> . 2022;40(16_suppl):8028-8028.	<a href="https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8028">https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8028</a>
van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. <i>Lancet</i> . 2021;397(10272):410-427.	<a href="https://pubmed.ncbi.nlm.nih.gov/33516340/">https://pubmed.ncbi.nlm.nih.gov/33516340/</a>
Verkleij CPM, Frerichs KA, Broekmans M, et al. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. <i>Oncotarget</i> . 2020;11(45):4076-4081. Published 2020 Nov 10.	<a href="https://pubmed.ncbi.nlm.nih.gov/33227097/">https://pubmed.ncbi.nlm.nih.gov/33227097/</a>
White D, et al. Oral selinexor, pomalidomide, and dexamethasone (XPD) at recommended phase 2 dose in relapsed/refractory multiple myeloma (MM). Presented at: European Hematology Association meeting. 2021;virtual.	<a href="https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324731/darrell.white.oral.selinexor.pomalidomide.and.dexamethasone.28xpd29.at.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2035%2Aot_id%3D25572">https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324731/darrell.white.oral.selinexor.pomalidomide.and.dexamethasone.28xpd29.at.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2035%2Aot_id%3D25572</a>
Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. <i>Cancer Discov</i> . 2022;12(7):1625-1633.	<a href="https://pubmed.ncbi.nlm.nih.gov/35417527/">https://pubmed.ncbi.nlm.nih.gov/35417527/</a>

Resource	Address
<b>Zonder JA, et al. Early, deep, and durable responses, and low rates of CRS with REGN5458, a BCMAxCD3 bispecific antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma. Presented at: 2022 EHA Congress; June 9-12, 2022; Vienna, Austria. Abstract S189.</b>	<a href="https://comylive.cme-congresses.com/wp-content/uploads/2022/05/Hoffman.pdf">https://comylive.cme-congresses.com/wp-content/uploads/2022/05/Hoffman.pdf</a>